UNSPSC 51293404: Tofenacin

This classification denotes an antimuscarinic agent with the molecular formula C17H21NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, C4A112M10H chemically known as ethanamine, n-methyl-2-((2-methylphenyl)phenylmethoxy)- but generally known as tofenacin, which bears US NIH Compound Identifier 25315. European Medicines Agency schedules Tofenacin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11142MIG. The term TOFENACIN is an International Non-Proprietary Name or INN.

Most nations schedule tofenacin under HS 29221980 and SITC 51461. As of Q4 2014, TOFENACIN remains the US FDA Preferred Term for this commodity. Tofenacin bears US NLM identifiers UMLS ID C0076783 and NCI Concept Code C81546. SMILES: CC1=CC=CC=C1C(C2=CC=CC=C2)OCCNC.

UNSPSC 51293404 Tofenacin is a Commodity code that in practice does not align with the recent state and local solicitations tagged under it. The three most recent opportunities involve naloxone distribution and safe drug deactivation systems procurement (Seminole County, Florida), a therapeutic pharmacy initiative to establish direct manufacturer relationships (Texas Health and Human Services Commission), and a multistate cooperative purchasing agreement for generic pharmaceuticals and OTC products (Minnesota Multistate Cooperative Purchasing Alliance). None of these solicitations address tofenacin specifically — a pharmaceutical active ingredient with limited visibility in state and local contracting activity. The code shows minimal recent relevant procurement activity; state and local buyers appear to tag pharmacy and drug supply chain work under this code without regard to its nominal scope.

Issuing bodies include county health departments, state health agencies, and multistate cooperative purchasing alliances. Seminole County, Florida posted an IFB (due July 26, 2023) for naloxone and drug deactivation systems with quarterly delivery requirements and a two-year initial term plus one-year renewal option. The Texas HHS Commission issued an RFI (deadline April 3, 2026) to gather vendor capabilities for direct-to-manufacturer prescription programs. The Minnesota Department of Administration's MMCAP posted an RFP (due March 26, 2026) for generic multi-source pharmaceuticals and OTC products for distribution through three authorized wholesalers (AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson Co.), with contract awards effective July 1, 2026, and a two-year initial term. Geographic activity appears concentrated in Florida, Texas, and Minnesota, with Oregon participating in the MMCAP cooperative agreement. The code does not support a clear buying pattern for tofenacin or a cohesive procurement strategy across these jurisdictions.